key: cord-1053464-j9x715rz authors: Yuki, Koichi; Fujiogi, Miho; Koutsogiannaki, Sophia title: COVID-19 pathophysiology: A review date: 2020-04-20 journal: Clin Immunol DOI: 10.1016/j.clim.2020.108427 sha: 5fe5b100a6790d1d73017e458c3fe7d94137ca7b doc_id: 1053464 cord_uid: j9x715rz Abstract In December 2019, a novel coronavirus, now named as SARS-CoV-2, caused a series of acute atypical respiratory diseases in Wuhan, Hubei Province, China. The disease caused by this virus was termed COVID-19. The virus is transmittable between humans and has caused pandemic worldwide. The number of death tolls continues to rise and a large number of countries have been forced to do social distancing and lockdown. Lack of targeted therapy continues to be a problem. Epidemiological studies showed that elder patients were more susceptible to severe diseases, while children tend to have milder symptoms. Here we reviewed the current knowledge about this disease and considered the potential explanation of the different symptomatology between children and adults. In December 2019, a series of acute atypical respiratory disease occurred in Wuhan, China. This rapidly spread from Wuhan to other areas. It was soon discovered that a novel coronavirus was responsible. The novel coronavirus was named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, 2019-nCoV) due to its high homology (~80%) to SARS-CoV, which caused by this virus was called Coronavirus disease 19 (COVID-19) and a pandemic was declared by the World Health Organization (WHO). COVID-19 has been impacting a large number of people worldwide, being reported in approximately 200 countries and territories (3, 4) . As of April 7th, 2020, around 1,400,000 cases worldwide have been reported according to the Center for Systems Science and Engineering (CSSE) at John Hopkins University (5). SARS-CoV-2 virus primarily affects the respiratory system, although other organ systems are also involved. Lower respiratory tract infection related symptoms including fever, dry cough and dyspnea were reported in the initial case series from Wuhan, China (6) . In addition, headache, dizziness, generalized weakness, vomiting and diarrhea were observed (7) . It is now widely recognized that respiratory symptoms of COVID-19 are extremely heterogeneous, ranging from minimal symptoms to significant hypoxia with ARDS. In the report from Wuhan mentioned above, the time between the onset of symptoms and the development of ARDS was as short as 9 days, suggesting that the respiratory symptoms could progress rapidly (6) . This disease could be also fatal. A growing number of patients with severe diseases have continued to succumb worldwide. Epidemiological studies have shown that mortalities are high in elder population (8) and the incidence is much lower in children (9, 10) . Current medical management is largely supportive with no targeted therapy available. Several drugs including lopinavir-ritonavir, remdesivir, hydroxychloroquine, and azithromycin have been tested in clinical trials (8, 11, 12) , but none of them have been proven to be a definite therapy yet. More therapies are being tested in clinical trials. A large number of countries have implemented social distancing and lockdown to mitigate further spread of the virus. Here we will review our current knowledge of COVID-19 and consider the underlying mechanism to explain the J o u r n a l P r e -p r o o f Journal Pre-proof heterogeneous symptomatology, particularly focusing on the difference between children and adult patients. A large number of studies so far are reports based on experiences in China. At the beginning of the outbreak, COVID-19 cases were mostly observed among elderly people (13) . As the outbreak continued, the number of cases among people aged 65 years and older increased further, but also some increase among children (< 18 years) was observed. The number of male patients was higher initially, but no significant gender difference was observed as case number increased. The mean incubation period was 5.2 days. The combined case-fatality rate was 2.3% (14, 15) . The risk factors of in-hospital death were studied using the data of two hospitals in Wuhan. Older age, higher sequential organ failure assessment (SOFA) score and d-dimer > 1 µg/mL on admission were shown to be risk factors in the multi-variable analysis (8) . In the univariable analysis, the presence of coronary artery disease, diabetes and hypertension was also considered to be risk factors. The study of 85 fatal COVID-19 patients with median age of 65 years in Wuhan showed that the majority of patients died from multi-organ failure as respiratory failure, shock, and ARDS were seen in 94%, 81%, and 74% of cases, respectively (16). As in line with the high prevalence of multi-organ failure, high d-dimer levels, fibrinogen and prolonged thrombin time were seen in severe diseases (17). Following the outbreak in China, SARS-CoV-2 has spread worldwide. As of early April, 2020, the reported number of COVID-19 patients is highest in the U.S., followed by Spain, Italy, Germany, France and China. Italy was significantly affected after the outbreak of China. Fatality rate was also higher in elder population as in Chinese series. The report from Italy showed the case-J o u r n a l P r e -p r o o f Journal Pre-proof fatality rate of 7.2% (15, 18), which was three times as high as the one in China. Although the case-fatality rate of patients aged 70 years or older was higher in Italy, it was very similar between age 0 and 69 years in both countries. As 23% of Italian was aged 65 years or older, the high case-fatality in Italy was somewhat explained by the demographic characteristics. The data from US and other countries is available in the number of resources (5, 19). We expect to learn experiences more from individual countries in the forthcoming future. From the beginning of this outbreak, the percentage of children within the total COVID-19 patients was small. According to the data of the Chinese Center for Disease Control and Prevention (China CDC) from February 2020, children younger than 10 years of age and within the age of 11-19 years occupied 1% each of the total cases (14) . Considering this age group represents 20% of the total population, this may indicate less prevalence of COVID-19 in pediatric population. However, this may be underestimation of actual incidence in pediatric population if less tests were undertaken in children due to less symptoms. One confounding factor is that schools in China were closed for most of the epidemic due to the Chinese New Year holidays, which might have contributed to less exposure among children. In the report of 2134 pediatric patients with COVID-19 from the China CDC, 4.4%, 50.9%, 38.8%, and 5.9% of patients were diagnosed as asymptomatic, mild, moderate, or severe, respectively (20). The years occupied only 1.2% (18). The case-fatality rate of age group 0-9 and 10-19 was 0% and 0.2%, respectively, which was similar to Chinese experience. In the data from the Korean CDC on late March, 6 .3% of all cases tested positive for COVID-19 were children under 19 years of age (21). On April 6, 2020, the US CDC released the study of 2,572 COVID-19 cases among children younger than 18 years (22). Of all reported cases in the US, this occupied only 1.7% of the total cases, even though this age group makes up 22% of US population. Overall, the data suggested that children were less symptomatic than adults as in Chinese reports. Among the children for whom complete information was available, only 73% developed fever, cough, or shortness of breath. That's compared to 93% of adults reported in the same time frame, between the ages of 18 and 64 years. The estimated hospitalization rate for children aged 1 to 17 was 14% at most (22). In contrast, infant accounted for the highest percentage of hospitalization (15-62%), which was again similar to the data from Chinese CDC. Despite the overall favorable outcome for pediatric population, a number of deaths have been reported in US and other countries, and further information needs to be obtained. Regarding the severity of COVID-19, there is a growing interest in the relationship between the severity of disease and gender. Although the Chinese series showed equal number of cases between males and females, the data suggested that more men than women suffered from severe disease and died (23, 24). The data from other countries demonstrated similar results (25). Adverse outcomes of COVID-19 were associated with comorbidities, including hypertension, cardiovascular disease, and lung disease. These conditions are more prevalent in men and linked to smoking and drinking alcohol (25). Sex-based immunological differences were pointed out as another potential explanation (13) . In addition, the study to examine J o u r n a l P r e -p r o o f Journal Pre-proof factors influencing the adoption of protective behaviors, specifically within the context of pandemics, found that women were about 50% more likely to practice non-pharmaceutical behaviors, suchg as hand washing, face mask use and avoiding crowds compared to men (26), which may be in part responsible. CoV-2 also bound to ACE2(31-33). ACE2 expression was high in lung, heart, ileum, kidney and bladder (34). In lung, ACE2 was highly expressed on lung epithelial cells. Whether or not SARS-CoV-2 binds to an additional target needs further investigation. Following the binding of SARS-CoV-2 to the host protein, the spike protein undergoes protease cleavage. A two-step sequential protease cleavage to activate spike protein of SARS-CoV and MERS-CoV was proposed as a model, consisting of cleavage at the S1/S2 cleavage site for priming and a cleavage for activation at the S'2 site, a position adjacent to a fusion peptide within the S 2 subunit (35-37). After the cleavage at the S1/S2 cleavage site, S 1 and S 2 subunits remain noncovalently bound and the distal S 1 subunit contributes to the stabilization of the membraneanchored S 2 subunit at the prefusion state (32). Subsequent cleavage at the S'2 site presumably activates the spike for membrane fusion via irreversible, conformational changes. The coronavirus spike is unusual among viruses because a range of different proteases can cleave and activate it (38) . The characteristics unique to SARS-CoV-2 among coronaviruses is the existence of furin cleavage site ("RPPA" sequence) at the S1/S2 site. The S1/S2 site of SARS-CoV-2 was entirely subjected to cleavage during biosynthesis in a drastic contrast to SARS-CoV spike, which was incorporated into assembly without cleavage (32). Although the S1/S2 site was The symptom of patients infected with SARS-CoV-2 ranges from minimal symptoms to severe respiratory failure with multiple organ failure. On Computerized tomography (CT) scan, the characteristic pulmonary ground glass opacification can be seen even in asymptomatic patients (40) . Because ACE2 is highly expressed on the apical side of lung epithelial cells in the alveolar space (41, 42) , this virus can likely enter and destroy them. This matches with the fact that the early lung injury was often seen in the distal airway. Epithelial cells, alveolar macrophages and dendritic cells (DCs) are three main components for innate immunity in the airway (43) . DCs These cytotoxic T cells can kill virus but also contribute to lung injury (58) . Circulating monocytes respond to GM-CSF released by these pathological T cells. CD14 + CD16 + inflammatory monocyte subsets, which seldom exist in healthy controls and were also found at significantly higher percentage in COVID-19 patients. These inflammatory CD14 + CD16 + monocytes had high expression of IL-6, which likely accelerated the progression of systemic inflammatory response. An interesting note is that ACE2 was significantly expressed on innate lymphoid cells (ILC)2 and ILC3 (Fig. 1) . NK cells are a member of ILC1, which constitute a large portion of ILCs in the lung (~95%). ILC2 and ILC3 work for mucous homeostasis. So far there is a very limited study of ILC2 and ILC3 in coronavirus infection. In addition, respiratory symptom, thrombosis and pulmonary embolism have been observed in severe diseases. This is in line with the finding that elevated d-dimer and fibrinogen levels were observed in severe diseases. The function of the endothelium includes promotion of vasodilation, fibrinolysis, and anti-aggregation. Because endothelium plays a significant role in thrombotic regulation (59) , hypercoagulable profiles seen in severe diseases likely indicate significant endothelial injury. Endothelial cells also express ACE2 (60, 61) . Of note, the endothelial cells represent the one third of lung cells (62) . Microvascular permeability as a result of the endothelial injury can facilitate viral invasion., and they may contribute Infants and young children are typically at high risk for admission to hospitals due to respiratory tract infection with viruses as respiratory syncytial virus and influenza virus. In contrast, pediatric COVID-19 patients have relatively milder symptoms in general compared to elder patients. The reason for this difference between children and adults remains elusive. Because the recent report suggested the correlation between the severity of COVID-19 and the amount of viral loads (or the duration of virus-shedding period) (63), children may have less virus loads even if they get COVID-19. In this line, a couple of hypotheses can be considered. The first possibility is that the expression level of ACE2 may differ between adults and children. A previous study showed that ACE2 was more abundantly expressed on well-differentiated ciliated epithelial cells (42) . Human lung and epithelial cells continue to develop following the birth. ACE2 expression may be lower in pediatric population. From the lung gene expression analysis portal (https://research.cchmc.org/pbge/lunggens/mainportal.html), ACE2 expression in mice increased around at birth (Fig. 2) . Its expression reduced till around P10, then increased. Because infants were susceptible to severe disease among children, this pattern may be in line with patients' clinical picture. In addition, gender may also affect ACE2 expression. ACE2 gene is located on the X-chromosome. Circulating ACE2 levels are higher in men than in women (64) . This may be in part responsible for the difference in severity and mortality between men and women both in the adult and the pediatric population (22-24). The second possibility is that children have a qualitatively different response to the SARS-CoV-2 virus to adults. With ageing, continuous antigen stimulation and thymic involution leads to a shift in T cell subset distribution from naïve T cells to central memory T cells, effector T cells and effector memory T cells (65) . This process is accompanied by the loss of expression of costimulatory molecules such as CD27 and CD28, with increased susceptibility to infections (66) . Whether the appearance of pathological T cells in adult patients with severe COVID-19 diseases is due to the compensation for this fundamental aging process or not is unclear. At the early stage after birth, CD4 + T cells are impaired in production of Th1 associated proinflammatory cytokines and skewed toward Th2 (67) . CD8 + T cells reduced expression of cytotoxic and inflammatory mediators. Less killing ability by T cells at early stage after birth may explain susceptibility to SARS-CoV-2 in infants. The study comparing aged and young macaques infected with SARS-CoV showed that aged macaques had more robust proinflammatory responses with worse lung pathology (68) . A similar result was reported using aged and young mice infected with SARS-CoV (69) .Severe COVID-19 infection is characterized by a massive proinflammatory response or cytokine storm that results in ARDS and multi-organ dysfunction (MODS). It has been also suggested that inflammatory responses in adults and children are much different (70) . Ageing is associated with increasing proinflammatory cytokines that J o u r n a l P r e -p r o o f govern neutrophil functions and have been correlated with the severity of ARDS. So far there is no animal model for SARS-CoV-2, but we expect to see a preclinical model in the future. The third possibility is that the simultaneous presence of other viruses in the mucosa lungs and airways, common in young children, can let SARS-CoV-2 virus compete with them and limit its growth (71) . At this point, we do not have study testing various viruses along with SARS-CoV-2 to determine this possibility. It is possible that a combination of these possibilities explains pediatric and adult COVID-19 phenotypes. Understanding why children in general are less susceptible to severe COVID-19 would help to design immunotherapy to eradicate this virus. The pandemic by COVID-19 is a live issue affecting people worldwide. Without fundamental therapeutic interventions, current management is to reduce the virus spread and provide supportive care for diseased patients. There is an urgent need to develop targeted therapies. Understanding the difference in pediatric and adult responses to this virus may help to direct immune based therapeutics. A novel coronavirus associated with severe acute respiratory syndrome GM Leung and Z Feng. 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Functional exhaustion of antiviral lymphocytes in COVID-19 patients Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study GWK Wong and T Chinese Pediatric Novel Coronavirus Study. 2020. SARS-CoV-2 Infection in Children Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Mechanisms of coronavirus cell entry mediated by the viral spike protein SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor NS Zhong and C China Medical Treatment Expert Group for. 2020. Clinical Characteristics of Coronavirus Disease Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells Virus clearance through apoptosisdependent phagocytosis of influenza A virus-infected cells by macrophages CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Dysregulation of immune response in patients with COVID-19 in Wuhan High levels of circulating GM-CSF(+)CD4(+) T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pulmonary Pathology of Early-Phase Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury The Use of Volatile Anesthetics as Sedatives for Acute Respiratory Distress Syndrome Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection CD8(+) T cell-mediated injury in vivo progresses in the absence of effector T cells Thrombotic Regulation From the Endothelial Cell Perspectives Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions Human pulmonary microvascular endothelial cells support of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection Viral dynamics in mild and severe cases of COVID-19 Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment Age related human T cell subset evolution and senescence Airway CD8(+) T Cells Are Associated with Lung Injury during Infant Viral Respiratory Tract Infection Exacerbated innate host response to SARS-CoV in aged non-human primates A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice Leukocyte subsetderived genomewide expression profiles in pediatric septic shock Virus -virus interactions impact the population dynamics of influenza and the common cold Journal 4:e2318. Highlight  In general, children are less susceptible to severe CODIV-19 than elder patients.  Adult COVID-19 patients with severe diseases showed higher proinflammatory markers There is a limited data of pediatric immune response to COVID-19